Guardant Health Weighing NeoGenomics Acquisition: Bloomberg

Bloomberg reported that Guardant Health Inc GH is reportedly exploring an acquisition of NeoGenomics Inc NEO, citing people familiar with the matter.
Related: Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates.
According to the sources, the companies have held discussions about a possible deal.
Deliberations are ongoing, and there’s no certainty they’ll lead to an offer from Guardant, the people said.
NeoGenomics offers diagnostic services to oncologists, pathologists, pharma companies, and academic centers to aid in treating cancers.
Related: NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance.
Price Action: NEO stock increased 2.11% at $49.26, while GH stock fell 13.1% at $118.67 during the market session on the last check Friday.